McNerney Megan E, Godley Lucy A, Le Beau Michelle M
Department of Pathology and the Department of Pediatrics, The University of Chicago, Chicago, Illinois 60637, USA.
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois 60637, USA.
Nat Rev Cancer. 2017 Aug 24;17(9):513-527. doi: 10.1038/nrc.2017.60.
Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or radiation administered for a primary condition, typically a malignant disease, solid organ transplant or autoimmune disease. Survival is measured in months, not years, making t-MN one of the most aggressive and lethal cancers. In this Review, we discuss recent developments that reframe our understanding of the genetic and environmental aetiology of t-MN. Emerging data are illuminating who is at highest risk of developing t-MN, why t-MN are chemoresistant and how we may use this information to treat and ultimately prevent this lethal disease.
治疗相关的髓系肿瘤(t-MN)是作为针对原发性疾病(通常是恶性疾病、实体器官移植或自身免疫性疾病)进行化疗和/或放疗的晚期效应而出现的。其生存期以月而非年计算,这使得t-MN成为最具侵袭性和致命性的癌症之一。在本综述中,我们讨论了一些最新进展,这些进展重塑了我们对t-MN的遗传和环境病因学的理解。新出现的数据揭示了哪些人患t-MN的风险最高、t-MN为何对化疗耐药,以及我们如何利用这些信息来治疗并最终预防这种致命疾病。